Before you begin…
Please review the following Abstract Instructions:

Presentation Format for Online Submission:

Title: Type in capitals and lower case.

Authors: Omit degrees and titles. Type presenting author name IN ALL CAPITALS with LAST, FIRST and MIDDLE INITIAL; for other authors use capitals and lower case with last names and initials only (e.g., Jones PL). Separate authors names with commas.

Organization of Abstract: Type your abstract directly into the online web form or copy/paste from a word-processing application. The body of the abstract should include a statement of the purpose (or objectives) of the study, a statement of the methods used, a summary of the results presented in sufficient detail to support the conclusions, and a statement of the conclusions reached. It is not satisfactory to use phrases such as “the results will be discussed” or “other data will be presented.”

Use the following headlines to clearly identify each element of content: Objectives, Methods, Results, Discussion and Conclusion. A Discussion section is optional.

Here is an example:

Radionuclide Imaging of Canine Mammary Tumors with Thallium-201, Tc-99m Sestamibi and F-18 Fluorodeoxyglucose

Objectives: The naturally-occurring canine mammary tumor was studied as an imaging model of human breast cancer. Nine tumors in eight dogs were evaluated by radionuclide imaging with Tl-201, Tc-99m Sestamibi, and positron emission tomography using F-18-FDG, plus biopsy.

Methods: Biopsy revealed 3 adenomas, 3 mixed mammary tumors, 2 enlarged mammary glands and 1 adenocarcinoma. Each tumor was evaluated by tomographic imaging and semi-quantitation.

Results: Thallium-201 uptake was present in 6 tumors out of 9. When comparing uptake in the tumor to uptake in the adjacent normal gland, the ratio range for benign tumors was 0.9-1.2 and the ratio for the carcinoma was 1.8. Tc-99m Sestamibi uptake was positive in 3 tumors, with a ratio range of 0.9-1.1 for benign and carcinoma. There was increased F-18 FDG activity in 8 tumors with SUV ranging from 0.4-0.9 for benign and an SUV of 2.5 for the carcinoma.

Discussion: Visual imaging with these agents could not differentiate benign from malignant tumor. Semi-quantitation with Tc-99m Sestamibi showed no difference in uptake between benign and malignant tumors while Tl-201 uptake ratios have a possible range cut-off. The F-18 FDG SUV showed a definite differentiation between benign and malignant tumors.

Conclusions: These results show that the naturally-occurring canine mammary tumor is a satisfactory imaging model of human breast cancer.

Submission: An abstract submission will be sent electronically to the SECSNMMI. An acknowledgement will be sent to you upon review of the abstract. Send optional supporting data, as a word document, to Include the abstract title and author names in the message.

Scientific and Educational Abstract Submission Grading Guidelines
All submissions to the SECSNMMI will utilize the following criteria with which your research/educational abstracts are rated:


  • Explanation of background (i.e. how you came up with your topic)
  • Originality
  • Educational
  • Applies to practice


  • Topic originated from student (if applicable)
  • The way in which you designed your method
  • Thoroughness of topic


  • Introduction
  • Hypothesis(for research abstracts)/Objective(for educational abstracts)
  • Methods
  • Results
  • Conclusion/Discussion
  • References

All submissions will receive a graded abstract upon notification of abstract acceptance/denial.

Click to Continue to Abstract Submission Form >>